Related Experiment Video
Updated: May 14, 2026
10:05
In Vitro Multiparametric Cellular Analysis by Micro Organic Charge-modulated Field-effect Transistor Arrays
Published on: September 20, 2021
Development of high resolution, multiplexed electrode arrays: Opportunities and challenges
Jonathan Viventi1, Justin A Blanco
1Department of Electrical and Computer Engineering, Polytechnic Institute of New York University, Brooklyn, NY 11201, USA.
Summary
New brain devices using flexible silicon nanoribbons offer hope for drug-resistant epilepsy. These advanced electrodes map seizure networks, potentially improving surgical outcomes and reducing neurological deficits for epilepsy patients.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Medical Devices
Background:
- Epilepsy affects 60 million globally, with over a third experiencing drug-resistant seizures.
- Current epilepsy surgery success rates are low (35%), with risks of neurological deficits.
- Technological limitations in brain interfacing hinder precise mapping of epileptic networks.
Purpose of the Study:
- To develop novel implantable brain devices for detailed mapping of epileptic networks.
- To overcome the technological barriers in treating drug-resistant epilepsy.
Main Methods:
- Development of flexible silicon nanoribbon-based implantable brain devices.
- Incorporation of thousands of individually controllable microelectrodes with inter-electrode distances of 0.5 mm or less.
- Scalability of devices to clinically relevant sizes (approx. 64 cm²).
Main Results:
- The developed devices enable high-resolution recording from small brain regions.
- The technology is scalable to cover large brain areas for comprehensive network mapping.
- These devices represent a significant advancement in brain-computer interfaces for epilepsy.
Conclusions:
- The new nanoribbon-based devices address a critical technological gap in epilepsy treatment.
- This technology holds promise for improving the efficacy and safety of epilepsy surgery.
- Further development could lead to more personalized and effective treatments for drug-resistant epilepsy.
